Sign in
Download Opera News App

Disease-prevention-and-treatment

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

Sulanda® is Chi-Med's first oncology drug brought to market without a partnership and the company's second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptable risk/benefit ratio – – ~400-strong oncology commercial team in place to...

Read Full Story
Chi-Med China NMPA PFS Sulanda Surufatinib